Cigarette Smoking Clinical Trial
Official title:
Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment
To test whether naltrexone compared to placebo can reduce heavy drinking and improve smoking cessation outcomes in heavy drinkers seeking smoking cessation treatment.
A substantial portion of individuals seeking behavioral and pharmacological treatment for
smoking cessation drink excessively with many reporting significant alcohol problems.
Although these at-risk and problem drinkers are unlikely to choose abstinence from alcohol
as a goal, many make substantial reductions in their drinking during and after their quit
smoking attempt. Thus, the context of smoking cessation treatment offers a unique and
valuable opportunity in which to apply brief interventions and pharmacotherapy to catalyze
change in excessive drinking in a population with markedly elevated risk for negative health
outcomes. In our recent randomized clinical trial, standard smoking cessation treatment that
incorporated a brief alcohol intervention showed promise in reducing drinking as well as in
improving smoking cessation outcomes among heavy drinkers. However, these effects were
relatively modest, especially among the heaviest drinkers, indicating that further study is
warranted of methods to address heavy drinking in smoking cessation including the use of
relevant pharmacotherapy. Naltrexone, in particular, shows promise for this purpose.
The overall aim of this project is to test the efficacy of naltrexone as a pharmacotherapy
for excessive drinking when delivered to at-risk or problem drinkers who are seeking smoking
cessation treatment. The proposed clinical trial uses a between-subjects design in which 300
at-risk or problem drinkers seeking treatment for smoking cessation will be randomly
assigned to receive either daily 50 mg naltrexone or placebo. Medication will be initiated 2
weeks prior to participants' smoking quit date and continue for 10 weeks. All participants
also will receive transdermal nicotine patch and a counseling and medication management
intervention that provides advice for smoking cessation, advice regarding the effects of
heavy drinking on both smoking cessation and health, and monitoring and encouragement of
compliance with medications. Drinking and smoking outcomes will be assessed at 2, 8, 16, and
26 weeks after participants' smoking quit date. The primary aim of the study is to test the
hypothesis that naltrexone will result in greater reductions in heavy drinking relative to
placebo. The secondary aim will test whether naltrexone results in superior smoking outcomes
relative to placebo, and tertiary aims will examine interrelationships among motivation for
changing drinking, compliance with naltrexone, and drinking and smoking outcomes.
This study represents the first of its kind to provide naltrexone in conjunction with an
opportunistic brief alcohol intervention for at-risk and problem drinkers not seeking
alcohol treatment. Testing the potential benefits of naltrexone among at-risk and problem
drinkers who smoke is of very high significance for public health efforts to reduce the
markedly elevated rates of morbidity and mortality observed in this large, yet relatively
understudied group.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Active, not recruiting |
NCT02643914 -
Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
|
N/A | |
Recruiting |
NCT02422914 -
Benefits of Tobacco Free Cigarette
|
N/A | |
Active, not recruiting |
NCT02629679 -
Sports, Education and Consumption of Substances in Adolescents
|
N/A | |
Completed |
NCT02385227 -
Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes
|
N/A | |
Completed |
NCT02218281 -
Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation
|
N/A | |
Completed |
NCT01199380 -
Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
|
Phase 2 | |
Completed |
NCT00802919 -
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
|
Phase 4 | |
Completed |
NCT01692353 -
Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers
|
N/A | |
Completed |
NCT00756704 -
The Effectiveness of Smoking Cessation Guidelines in the Emergency Department
|
N/A | |
Completed |
NCT01081119 -
Brief Voluntary Alcohol and Drug Intervention for Middle School Youth
|
Phase 2 | |
Completed |
NCT00682474 -
School Nurse-Delivered Smoking Cessation Intervention
|
Phase 2/Phase 3 | |
Completed |
NCT05520775 -
Semaglutide for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT03743532 -
E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services
|
N/A | |
Terminated |
NCT03840694 -
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior
|
N/A | |
Completed |
NCT06032793 -
Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.
|
N/A | |
Terminated |
NCT03326128 -
High Dose Bupropion for Smoking Cessation - Pilot Study
|
Phase 2 | |
Recruiting |
NCT03218670 -
Your Health in On Click
|
N/A | |
Completed |
NCT02538042 -
Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)
|
N/A |